Celladon Hopes To Bring Gene-Therapy Solution To Heart Failure Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Improving heart contractility by increasing levels of the SERCA2a gene is a new approach to a familiar problem in treating heart failure.
You may also be interested in...
Recent Breakthrough Designations Break New Ground
Vaccines and gene therapies are added to the list of types of drugs that could garner the expedited development pathway from the U.S. regulatory agency, with Novartis and Celladon being the most recent companies to tout the status.
Recent Breakthrough Designations Break New Ground
Vaccines and gene therapies are added to the list of types of drugs that could garner the expedited development pathway from the U.S. regulatory agency, with Novartis and Celladon being the most recent companies to tout the status.
The Unlikely Renaissance Of Gene Therapy
After a decade of doubts, fears, and scares, advances in gene therapy have brought one drug close to approval, and a few venture-backed start-ups are gaining momentum. Is it enough to persuade more VCs to jump in?